The Department of War must maintain an integrated pharmacy benefits program for the Military Health System, with a Pharmacy and Therapeutics Committee evaluating the clinical and cost effectiveness of pharmaceutical agents for formulary placement. An RFQ process supports this by obtaining industry quotes for drug classes under review, potentially leading to Uniform Formulary Blanket Purchase Agreements and Additional Discount Program Agreements. The upcoming P&T Committee meeting in November 2026 will review four newly approved drugs: Awiqli Flextouch, Cavhanza, Lipfendra, and Trutakna. A pre-quotation teleconference is scheduled for August 12, 2026. The RFQ package includes instructions, appendices, and points of contact for interested vendors.